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 Abstract 
 Background: In resource-limited settings the monitoring of tuberculosis (TB) patients is challenging, and early identifi cation 
of TB patients with a high mortality risk is important. The aim of this study was to investigate prospectively whether early 
changes in a clinical scoring system (TB score) can predict treatment outcome in Ethiopian patients with pulmonary 
tuberculosis.  Method: TB patients ( n    250) and blood donors ( n    82) were recruited prospectively at Gondar University 
Hospital, Ethiopia. Clinical scoring was performed using an interview-based questionnaire and clinical examination.  Results: 
Among TB patients (53.6% of whom were HIV co-infected) the median TB score declined from week 0 to week 2 (8 
(interquartile range (IQR) 6 – 9) vs 4 (IQR 2 – 6)) and dropped to a low level at week 8, which was still signifi cantly higher 
than that found in blood donors (2 (IQR 1 – 4) vs 0 (IQR 0 – 1),  p    0.0001). Patients who died had a signifi cantly higher 
TB score at week 0, week 2, and week 8 than survivors. Mortality was associated with a failure to achieve a decrease greater 
than 25% in the TB score at 2 weeks. Baseline CD4   cell counts (   200 cells/mm 3 ) were associated with mortality but 
not with initial TB score results.  Conclusions: The TB score was increased during the fi rst 2 months of treatment among 
patients who died. Failure to achieve a greater than 25% decrease in TB score after 2 weeks of treatment was associated 
with increased mortality. Repeated clinical scoring during the intensive phase of TB treatment could be useful to identify 
high-risk patients. 
 Keywords:  Tuberculosis ,  HIV ,  TB score ,  outcome ,  mortality 
 Introduction 
 The impact of tuberculosis (TB) is greatest in low-
income countries, both with regard to the burden of 
new cases and deaths due to TB [1]. Hitherto, no 
satisfactory method exists that can identify patients 
at high risk of death during TB treatment. In resource-
limited settings, it is diffi cult to monitor TB patients 
during treatment and still no surrogate marker for 
treatment response is accessible for smear-negative 
pulmonary TB patients. This is especially problem-
atic in the setting of HIV co-infection, in which such 
manifestations are more common [2]. 
 In this regard, laboratory biomarkers and radio-
logical follow-up have been shown to be both insen-
sitive and technically demanding [3]. Therefore, 
there is a need to develop cost-effective and simple 
parameters for predicting treatment outcome early. 
 A previous retrospective study in TB patients 
from Guinea-Bissau showed that clinical signs of 
immune defi ciency (such as oral Candida infection 
or oral hairy leukoplakia and diarrhoea), low body 
mass index (BMI), and low mid-upper arm circum-
ference (MUAC) were predictors of increased mor-
tality [4]. A recent systematic review also found that 
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HIV co-infection, advanced immunosuppression, 
smear-negative disease, and malnutrition were risk 
factors for mortality [5]. A previous meta-analysis has 
shown that it is possible to identify individuals with 
suspected TB using a simplifi ed screening algorithm 
based on clinical symptoms [6]. 
 Researchers from Guinea-Bissau have proposed 
a scoring system (TB score) based on clinical param-
eters for fi eld use in highly endemic areas, and have 
presented a retrospective evaluation of a cohort of 
698 patients treated for TB with regard to fi nal out-
come [7]. They showed that the score at the time of 
TB diagnosis could identify patients with a high risk 
of mortality [7]. Data on the performance of the TB 
score from other settings and its correlation with 
HIV co-infection and CD4   cell counts are limited. 
Repeated scoring during early treatment could 
increase the capacity of the TB score to identify 
patients at risk of mortality, as the majority respond 
with a clinical improvement within 2 weeks [1]. 
 The aim of our study was to investigate prospec-
tively whether early changes in TB scoring results can 
predict treatment outcome in Ethiopian patients with 
pulmonary tuberculosis and whether the TB score is 
infl uenced by HIV co-infection and CD4   cell 
levels. 
 Materials and methods 
 Study participants 
 Adult outpatients with pulmonary TB were prospec-
tively recruited at the directly observed treatment 
short-course (DOTS) clinic of Gondar University 
Hospital, Ethiopia between June 2007 and January 
2009. Inclusion criteria were a diagnosis of smear-
positive or smear-negative pulmonary TB, age 
between 18 and 65 y, and consent to HIV testing. 
Hospitalized patients, cases with isolated extrapul-
monary tuberculosis, and patients already taking 
anti-TB treatment were excluded. Smear-positive 
pulmonary TB was defi ned as a patient with at least 
2 sputum specimens positive for acid-fast bacilli 
(AFB) by microscopy, or a patient with 1 positive 
sputum specimen and chest radiographic abnormal-
ities consistent with active pulmonary TB [8]. Smear-
negative pulmonary tuberculosis was defi ned as 
symptoms suggestive of TB with 3 sputum smear 
samples negative for AFB, radiographic abnormali-
ties consistent with pulmonary TB, and a lack of 
clinical response to 1 week of broad-spectrum anti-
biotic therapy [8]. All patients received 2 months of 
daily directly observed treatment with ethambutol, 
isoniazid, rifampicin, and pyrazinamide, followed 
by a 6-month continuation phase with isoniazid 
and ethambutol, in accordance with the Ethiopian 
guidelines in practice at the time of the study. Treat-
ment was provided free of charge and no interrup-
tions in the drug supply were recorded during the 
study period. For comparison, HIV-seronegative 
adults without signs of active TB were recruited from 
blood donors at the blood bank, Gondar University 
Hospital. TB scoring including the clinical examina-
tion was performed by the 2 specially trained nurses 
at the DOTS centre at week 0 before the patients 
had started TB treatment, at week 2, and at week 8. 
Both patients and controls provided written informed 
consent. The study was approved by the Ethics 
Review Committee at the University of Gondar, 
Ethiopia and by the Regional Ethics Review Board, 
Link ö ping, Sweden. 
 Laboratory examinations 
 Sputum smear microscopy was repeated for all 
patients with positive sputum smears at baseline and 
at the end of months 2, 5, and 7 of treatment to 
defi ne the treatment outcome category [8]. CD4   cell 
counts were measured within 2 weeks of treatment 
initiation for all patients. HIV testing was done at the 
hospital voluntary counselling and testing clinic 
(VCT) or at the DOTS clinic as part of the provider-
initiated HIV counselling and testing programme 
(PIHCT), according to the hospital routine, using 
HIV rapid test kits (Determine  ®  HIV-1/2 Ag/Ab 
Combo (Orlando, FL, USA); Capillus (Trinity 
Biotech USA Inc., NY, USA); Unigold (Trinity 
Biotech USA Inc., NY, USA)). HIV-positive patients 
were referred to the hospital HIV clinic for further 
assessment and were managed according to the 
World Health Organization (WHO)-based Ethiopian 
national guidelines for antiretroviral treatment (ART) 
at the time of the study. The aim was that ART 
should be started as early as possible in TB patients 
with profound immune suppression (CD4 counts 
  50 cells/mm 3 ), and in HIV-infected patients with a 
CD4 count    50 cells/mm 3 , as soon as possible and 
primarily after the intensive phase of anti-TB treat-
ment. CD4   cell counts were analyzed using the 
FACSCount (BD Biosciences, San Jose, CA, USA). 
 TB score and clinical outcome data 
 Clinical scoring was performed according to Wejse et  al. 
[7] including the variables: cough, haemoptysis, dysp-
noea, chest pain, night sweating, anaemic conjunctivae, 
tachycardia (   100/min), lung auscultation (any abnor-
mal fi ndings), axillary temperature    37.0 ° C, body 
mass index (BMI)    18 kg/m 2 , BMI    16 kg/m 2 , MUAC
   220 mm, and MUAC    200 mm. Each variable con-
tributes 1 point and the maximum score is 13. Based 
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on TB score results the patients were divided into 3 
severity classes as previously described [7]: severity 
class I with a TB score of 0 – 5, severity class II with a 
TB score of 6 – 7, and severity class III when the TB 
score is    8. Treatment outcome categories were 
recorded for all patients at the end of treatment accord-
ing to WHO defi nitions (cured, treatment completed, 
treatment failure, died, defaulted, and transferred out) 
[8,9]. As per WHO defi nitions for TB treatment out-
come, all-cause mortality as well as other outcomes 
were registered in the DOTS register. If a patient failed 
to turn up for treatment, a tracer tried to fi nd the 
patient by contacting relatives or friends by domiciliary 
visits and treatment outcome was then registered. 
 Statistics 
 In order to detect a minimally clinical important dif-
ference of 1.1 TB score points [7] of the TB patients 
at week 8 compared to the blood donors, 80 blood 
donors were needed at a power of 80% (alpha 0.05). 
Moreover, we assumed that a sample size of 250 TB 
patients (including a 10% loss to follow-up) was 
needed in order to detect a mortality difference from 
the expected 8% to 18% in the patients who did not 
show a decrease in the TB score of    25% between 
baseline and week 2, on the assumption of a 10% 
overall mortality and an estimated fraction of 20% 
not reaching a    25% decrease between baseline and 
week 2. Data are presented as the median and inter-
quartile range. The data were analysed using Fisher ’ s 
exact test for categorical variables and Wilcoxon and 
Mann – Whitney tests for continuous variables. A 
 p -value below 0.05 was regarded as statistically 
signifi cant. In a multiple logistic regression model 
applying mortality as the dependent variable (STA-
TISTICA software package; StatSoft, Tulsa, USA), 
age, sex, HIV, presence of ART treatment, and 
CD4   cell counts (   200 cells/mm 3 ) were included 
in the fi nal analysis. 
 Results 
 Patient characteristics 
 Baseline characteristics of the 250 study participants 
and the 82 blood donors are shown in Table I. The 
main reason for exclusion was hospitalization of 
smear-negative patients (264/446 excluded patients); 
a fl ow chart of patients is shown in Figure 1. The 
HIV co-infection rate was slightly although not sig-
nifi cantly higher in smear-negative than in smear-
positive patients (59.0% (63/107) vs 50.0% (71/143), 
 p    0.22). Among the 250 patients, excluding default-
ers and patients who died or who were transferred 
out, the TB score was not registered for 9 patients 
at week 2 and 22 could not be assessed at week 8 
(Figure 1, Table II). 
 Treatment outcome 
 The fi nal TB treatment outcome according to WHO 
was recorded in 248 of the 250 patients. Among the 
248 patients, 17 (7%) died, 173 (70%) were cured 
and/or completed treatment, 33 (13%) were trans-
ferred out, and 25 (10%) were defaulters. The all-
cause mortality was higher among HIV-positive TB 
patients (9.8%, 13/132) than HIV-negative TB 
patients (3.4%, 4/116;  p    0.039). The treatment 
outcomes are summarized in Table II. Although the 
exact time of death could not be defi ned, 11/17 
patients (64.7%) died within 8 weeks. 
 Association between longitudinal TB score results 
and treatment outcome 
 Overall, a decline in TB score was observed 
from week 0 to week 2 (data presented as median 
(interquartile range (IQR)): 8 (6 – 9) vs 4 (2 – 6), 
 p    0.0001). During further follow-up, the TB 
score continued to decline to a low level at week 
8; however, the score results were still signifi cantly 
higher at this time point than those observed in 
blood donors (2 (1 – 4) vs 0 (0 – 1),  p    0.0001). 
We found no difference in the TB score between a 
successful clinical response (cured and treatment 
completed) vs an unfavourable response (died 
or defaulted) at baseline (8 (6 – 9) vs 8 (6 – 10); 
excluding patients transferred out). However, 
there was a signifi cant difference in the TB score 
among these groups at week 2 (4 (2 – 5) vs 5 (2 – 7), 
 p    0.031) and at week 8 (2 (0 – 4) vs 5 (2 – 6), 
 p    0.0001). Moreover, we observed a signifi cantly 
higher TB score at week 0 (9 (7 – 10) vs 8 (6 – 9)), 
week 2 (7 (5 – 8) vs 4 (2 – 5)), and at week 8 (5 (4 – 7) 
vs 2 (0 – 4)) among patients who died compared to 
those who achieved cure or treatment completion 
(Table II). Mortality was associated with a failure 
to achieve a 25% decrease in TB score at week 2 
( p    0.027). The kinetics of the TB score in this 
group, as well as in smear-positive and smear-
negative patients, is presented in Figure 2. The 
majority who died during follow-up were classifi ed 
as severity class III (70.6%) at baseline compared 
to those who were cured or completed treatment 
(52.0%) (Table III). Based on receiver operating 
characteristic curve (ROC) analysis (data not 
shown), a TB score cut-off of 9 could predict the 
risk of death with a sensitivity of 41% and a spec-
ifi city of 78%, which is similar to those reported 
elsewhere [7]. 
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Baseline, (n = 250)
Median TB score 8 (6–9)
TB score after 2 weeks, (n = 232)
Median TB score 4 (2–6)
TB score after 8 weeks, (n = 188)
Median TB score 2 (1–4)
Clinical follow-up (n = 248):
Cured and/or completed
treatment (n = 173)
Died (n = 17)
Defaulted (n = 25)
Transferred out (n = 33)
696 TB patients eligible for
inclusion
Excluded (n = 446):
Refused HIV testing (n = 12)
Hospitalized (n = 326)
Refused to participate (n = 73)
Retreatment cases (n = 11)
Transferred in or out (n = 24)
 
Figure 1. Flow chart of patients. 
 Table I. Baseline characteristics of study participants. 
HIV-pos TB a 
 ( n    134, 53.6%)
HIV-neg TB
 ( n    116, 46.4%)
Reference group
 ( n    82)
Age, y; median (IQR) 30 (26 – 37) 24 (20 – 28) 27 (23 – 36)
Males,  n (%) 63 (47) 70 (60) 78 (95)
Smear-positive,  n (%) 71 (53) 72 (62) ND
CD4   cell count cells/mm 3 ; median (IQR) 157 (80 – 245) 
( n    96)
501 (390 – 664) 
( n    90)
ND
TB score week 0; median (IQR) 8 (6 – 9) 8 (6 – 9) 0 (0 – 1) b 
 HIV-pos, HIV-positive; HIV-neg, HIV-negative; TB, tuberculosis; ND, not determined; IQR, interquartile 
range. 
 a The data on gender was missing for 1 HIV-positive TB patient. 
 b The HIV-positive and HIV-negative TB patients versus the reference group,  p    0.0001. 
 Association between TB score results and treatment 
outcome with regard to HIV serostatus and 
CD4   cell counts 
 In a multivariate regression model, mortality was 
associated with an increased TB score (categorized 
0 – 5, 6 – 9, and    10) at week 0 (odds ratio 3.4, 95% 
confi dence interval 1.2 – 10.0,  p    0.023; Table IV) 
after adjusting for age, sex, HIV, presence of ART, 
and CD4   cell counts (   200 cells/mm 3 ). No differ-
ence was observed in the TB score at baseline (8 
(6 – 10) vs 8 (6 – 9)), week 2 (4 (2 – 6) vs 4 (3 – 6)), or 
at week 8 (2 (0 – 4) vs 2 (1 – 4)) between HIV-positive 
and HIV-negative individuals. The TB score was 8 
(6 – 9) among the HIV-negative TB patients with 
available CD4 cell results (90/116 patients). In HIV-
positive TB patients, the median TB score was 8 
(6 – 10) (data available for 96/134 patients, where 
59/96 individuals had a CD4   cell count    200 cells/
mm 3 (TB score 8 (6 – 9)). No correlation was found 
between the baseline TB score and the CD4   cell 
count, either overall or in HIV-positive subjects. 
However, the patients who died (4 HIV-negative and 
13 HIV-positive) had lower CD4   cell counts at 
baseline compared to the patients who completed 
treatment and the patients who were cured (133 
(85 – 260) vs 339 (158 – 521) cells/mm 3 ,  p    0.025). 
Regarding ART, 40% (54/134) of the HIV-positive 
patients were on ART during TB treatment. Almost 
half of them, 48.1% (26/54), had already initiated 
ART before they started TB treatment and the 
median time of ART initiation after TB treatment 
was 114 days. 
 Discussion 
 In this study, we prospectively evaluated a clinical 
scoring system (TB score) during the intensive phase 
of treatment in a cohort of Ethiopian pulmonary TB 
patients [7]. The majority of patients showed a sig-
nifi cant decline in the TB score results at 2 weeks 
after starting TB treatment, but the levels remained 
higher at week 8 than those found in the controls. A 
signifi cantly increased TB score at week 0 and the 
absence of a decline in score results by more than 
25% at 2 weeks were both associated with increased 
mortality. This suggests that repeated clinical scoring 
during the initial 8 weeks of TB treatment could be 
of value in routine practice to objectively identify 
high-risk patients. The early identifi cation of TB 
patients at risk of a poor outcome might be impor-
tant in high endemic areas in order to initiate tar-
geted interventions such as hospital admission, 
additional diagnostic investigations, and intensifi ed 
follow-up. Further research in this fi eld has recently 
been called for [10] and additional prospective stud-
ies are needed to confi rm that interventions based on 
a clinical scoring system such as the TB score have 
an impact on the TB-associated mortality. 
 The highest mortality rate was found in HIV-
positive patients (13/134) and in particular in patients 
with a low baseline CD4   cell count. Indeed, HIV 
infection appears to be the dominant risk factor for 
mortality among Ethiopian TB patients, and clinical 
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 Figure 2. Kinetics of the TB score. Data are presented as medians, 
and error bars indicate the interquartile range. The kinetics of 
smear-positive (fi lled squares) and smear-negative (unfi lled 
squares) TB patients, as well as patients exhibiting a    25% 
decrease (unfi lled triangles) and a    25% decrease in the TB score 
from week 0 to week 2, are illustrated. 
scoring and close monitoring should be prioritized 
for this group. It is well known that HIV-positive 
patients with TB have a high mortality risk [11,12]. 
A number of reasons contribute to this, including 
more severe disease, delayed diagnosis due to atypi-
cal presentation, co-existing opportunistic infections, 
delayed ART initiation, advanced immunodefi ciency, 
and TB drug resistance. Despite the absence of drug 
susceptibility testing in this study, no treatment fail-
ure case was detected, which indicates a relatively 
low level of drug resistance. 
 Our study has several limitations, including that 
survival at the end of treatment could not be assessed 
for a high proportion of patients (60/250; 24%). 
Moreover, the specifi c cause and time of death could 
not be determined. It is possible that there could 
have been undetected deaths in the defaulting group 
(10%) and to a lesser extent among the patients 
who were transferred out [13]. To take this into 
consideration, default was considered an unfavour-
able response in the analysis of favourable vs 
unfavourable clinical response in relation to the TB 
score [14]. 
 Although the national WHO-based strategy was 
used, another limitation of this study is that the 
smear-negative TB patients were not confi rmed by 
culture and that drug susceptibility testing was not 
performed. However, the external validity of our 
results is still likely to be high as the setting is similar 
to where most TB patients are diagnosed and treated. 
Moreover, a treatment response in relation to the TB 
score was observed in the majority of smear-negative 
TB patients at a similar rate as for the smear-positive 
TB patients, which indicates a treatment response to 
the anti-TB therapy. Our study could not determine 
whether the initiation of ART during TB treatment 
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 Table III. Association with treatment outcome according to the 3 severity classes of the 
TB score at week 0. 
Severity class I
 TB score 0 – 5
Severity class II
 TB score 6 – 7
Severity class III
 TB score    8
Cured or treatment completed 
week 0,  n (%)
29 (16.8) 54 (31.2) 90 (52.0)
Died,  n (%) 0 (0) 5 (29.4) 12 (70.6)
Defaulted,  n (%) 5 (20.0) 9 (36.0) 11 (44.0)
Transferred out,  n (%) 6 (18.2) 8 (24.2) 19 (57.6)
Not cured,  n (%) a 5 (11.9) 14 (33.3) 23 (54.8)
 TB, tuberculosis. 
 a Not cured includes patients who died or defaulted. 
 Table IV. Multivariate logistic regression analysis of the association between TB score and mortality at baseline 
adjusted for age, sex, HIV, ART, and CD4 count. 
Mortality Univariate Multivariate
Parameter  N  n % OR (95% CI)  p -Value OR (95% CI)  p -Value
Age, y
    28 137 9 6.6 1.00 1.00
    28 109 8 7.3 1.13 (0.42 – 3.04) 0.813 0.75 (0.19 – 2.92) 0.680
Gender
Female 131 14 10.7 1.00 1.00
Male 116 3 2.6 0.22 (0.06 – 0.80) 0.021 0.29 (0.07 – 1.23) 0.092
HIV
No 116 4 3.4 1.00 1.00
Yes 132 4 3.0 3.06 (0.96 – 9.71) 0.058 3.52 (0.47 – 26.46) 0.220
ART treatment
No 194 12 6.2 1.00 1.00
Yes 54 5 9.3 1.55 (0.52 – 4.63) 0.433 0.76 (0.17 – 3.30) 0.711
CD4 count
    200 120 4 3.3 1.00 1.00
    200 64 9 14.1 4.75 (1.39 – 16.22) 0.013 2.53 (0.50 – 12.87) 0.263
TB score week 0
0 – 5 40 0 0 1.00 1.00
6 – 9 150 10 6.7 2.68 (1.14 – 6.28) 3.45 (1.19 – 9.99)
    10 58 7 12.1 7.17 (1.30 – 39.47) 0.024 11.90 (1.42 – 99.81) 0.023
 TB, tuberculosis; ART, antiretroviral therapy; OR, odds ratio; 95% CI, 95% confi dence interval. 
was associated with decreased mortality and was not 
primarily designed for that purpose. 
 A major benefi t of the TB score is that it provides 
a simple tool for standardized evaluation of early 
clinical improvement in TB patients in high endemic 
areas. Early monitoring of patients with the TB score 
in the fi rst 2 months of treatment could facilitate the 
identifi cation of patients at high risk of a poor clini-
cal outcome. This relatively simple clinical score 
could provide an objective tool for healthcare work-
ers to identify high-risk patients. The TB score 
has demonstrated good inter- and intra-observer 
variability in an Indian setting and is easy to learn 
and to monitor [15]. The clinical evaluation can 
quickly be carried out without using expensive diag-
nostic tools and could be suitable for follow-up 
in clinical trials [7]. However, the scoring system 
needs further development to improve its capacity to 
predict clinical outcomes, especially with regard to 
HIV co-infection and parameters that are relevant in 
such patients. Furthermore, the defi nition of cut-off 
levels for practical use to pin-point high-risk patients 
needs to be explored in future studies, as well as how 
to implement the scoring algorithm at different levels 
of the healthcare system. 
 In conclusion, our study shows that the TB score 
can predict mortality among Ethiopian patients, and 
it may have a role in the follow-up of TB patients; 
this could be of use to target interventions and as a 
tool for evaluation in clinical trials. 
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